[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SV2018005723A - Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos - Google Patents

Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos

Info

Publication number
SV2018005723A
SV2018005723A SV2018005723A SV2018005723A SV2018005723A SV 2018005723 A SV2018005723 A SV 2018005723A SV 2018005723 A SV2018005723 A SV 2018005723A SV 2018005723 A SV2018005723 A SV 2018005723A SV 2018005723 A SV2018005723 A SV 2018005723A
Authority
SV
El Salvador
Prior art keywords
thiohidantoine
antagonists
derivatives substituted
androgen
receiver
Prior art date
Application number
SV2018005723A
Other languages
English (en)
Inventor
Gilles Bignan
Peter J Connolly
Ian Hickson
Lieven Meerpoel
Vineet Pande
Zhuming Zhang
Christian Rocaboy
Jonathan Branch
Escobar Luis B Trabalon
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SV2018005723A publication Critical patent/SV2018005723A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBEN COMPUESTOS, COMPOSICIONES Y MÉTODOS PARA TRATAR TRASTORNOS QUE SE AFECTAN POR EL ANTAGONISMO DE UNO O MÁS TIPOS DEL RECEPTOR DE ANDRÓGENOS. ESOS COMPUESTOS SE REPRESENTAN POR LA FÓRMULA (1) DE LA MANERA SIGUIENTE: FÓRMULA (I) DE LA MANERA SIGUIENTE: FÓRMULA (1) EN DONDE R1 Y G SE DEFINEN EN LA PRESENTE DESCRIPCIÓN.
SV2018005723A 2016-01-11 2018-07-10 Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos SV2018005723A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277009P 2016-01-11 2016-01-11
US201662363534P 2016-07-18 2016-07-18

Publications (1)

Publication Number Publication Date
SV2018005723A true SV2018005723A (es) 2019-01-28

Family

ID=57963446

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005723A SV2018005723A (es) 2016-01-11 2018-07-10 Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos

Country Status (22)

Country Link
US (3) US10000502B2 (es)
EP (1) EP3402791A1 (es)
JP (1) JP2019504836A (es)
KR (1) KR20180100214A (es)
CN (1) CN108473471A (es)
AU (3) AU2017207268B2 (es)
BR (1) BR112018014015A2 (es)
CA (1) CA3010509A1 (es)
CO (1) CO2018007738A2 (es)
CR (2) CR20180352A (es)
EA (1) EA037753B1 (es)
EC (1) ECSP18060342A (es)
IL (1) IL260307A (es)
MA (1) MA43864A (es)
MX (1) MX2018008502A (es)
NI (1) NI201800075A (es)
NZ (1) NZ744137A (es)
PH (1) PH12018501413A1 (es)
SG (1) SG11201805685PA (es)
SV (1) SV2018005723A (es)
TW (1) TWI726969B (es)
WO (1) WO2017123542A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
CA3030181A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
CN110167556A (zh) * 2016-07-08 2019-08-23 詹森药业有限公司 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂
EP3666772A4 (en) * 2017-08-07 2021-01-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
MX2021007475A (es) 2018-12-19 2021-08-05 Celgene Corp Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos.
PE20212247A1 (es) 2018-12-19 2021-11-24 Celgene Corp Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
CN110452166A (zh) * 2019-09-06 2019-11-15 浙江朗华制药有限公司 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法
CN115279769A (zh) * 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
WO2021143925A1 (zh) * 2020-01-19 2021-07-22 正大天晴药业集团股份有限公司 作为ar拮抗剂的二芳基硫代乙内酰脲化合物
US20230135524A1 (en) * 2020-01-21 2023-05-04 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
CN115650954A (zh) * 2022-10-24 2023-01-31 江苏海悦康医药科技有限公司 阿帕他胺有关物质的制备方法
WO2024102706A1 (en) * 2022-11-09 2024-05-16 Bristol-Myers Squibb Company Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4916937B1 (es) 1970-01-21 1974-04-25
US3823240A (en) 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE2614831A1 (de) 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
ZA786739B (en) 1977-12-01 1980-07-30 Wellcome Found Hydantoin derivatives and salts thereof,their syntheses,and intermediates,and pharmaceutical formulations
EP0004723A1 (en) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A (fi) 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS57197268A (en) 1981-05-29 1982-12-03 Sumitomo Chem Co Ltd Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
DE3382406D1 (de) 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) 1983-05-13 1984-11-28 Otsuka Chem Co Ltd １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
DE3604042A1 (de) 1986-02-08 1987-08-13 Hoechst Ag Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4859228A (en) 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de) 1988-10-15 1990-04-19 Bayer Ag N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
EP0748220A4 (en) 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
DE69519921T2 (de) 1994-07-29 2001-06-13 Suntory Limited, Osaka Imidazolidin-derivate und ihre verwendung
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
WO1997019931A1 (en) 1995-11-28 1997-06-05 American Home Products Corporation 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
TW418195B (en) 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
WO1998033772A1 (en) 1997-02-03 1998-08-06 Dow Agrosciences Llc 2-methoxyimino-2-(pyridinyloxymethyl)phenyl acetamides with carboxylic acid derivatives on the pyridine ring as fungicides
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1129581C (zh) 1998-09-22 2003-12-03 山之内制药株式会社 氰基苯基衍生物
DE19940211A1 (de) 1998-09-22 2000-03-23 Degussa Verfahren zur Herstellung von Imidazolidin-2,4-dionen
WO2000026195A1 (en) 1998-10-30 2000-05-11 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
AU2847200A (en) 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
US6350763B1 (en) 1999-07-21 2002-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammation disease
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
NZ522852A (en) 2000-05-31 2004-09-24 Tanabe Seiyaku Co Inhibitors of alpha L beta 2 mediated cell adhesion
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
US6710037B2 (en) 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
ES2339107T3 (es) 2001-10-01 2010-05-17 Bristol-Myers Squibb Company Compuestos de espiro hidantoina utiles como agentes anti-inflamatorios.
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US20060127902A1 (en) 2002-08-15 2006-06-15 Genzyme Corporation Brain endothelial cell expression patterns
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
US20060025589A1 (en) 2002-10-01 2006-02-02 Jean Binet 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2004252175A (ja) 2003-02-20 2004-09-09 Kyocera Mita Corp 現像装置、画像形成装置および現像剤の回収方法
AU2004247319A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
ES2625341T3 (es) 2003-06-12 2017-07-19 Astellas Pharma Inc. Derivado de benzamida o sal del mismo
EP1634874A4 (en) 2003-06-12 2008-04-02 Chugai Pharmaceutical Co Ltd imidazolidine
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
AU2004298604B2 (en) 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
CA2550447A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
CA2559545A1 (en) 2004-03-15 2005-09-29 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives for inhibiting angiogenesis
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
WO2006013887A1 (ja) 2004-08-03 2006-02-09 Chugai Seiyaku Kabushiki Kaisha 新規イミダゾリジン誘導体
EP1790640A4 (en) 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
NZ555974A (en) 2005-01-10 2010-11-26 Acadia Pharm Inc Aminophenyl derivatives as selective androgen receptor modulators
KR20240148945A (ko) 2005-05-13 2024-10-11 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
FR2889189A1 (fr) 2005-07-28 2007-02-02 Cerep Sa Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
EP1990335A4 (en) 2006-03-02 2009-11-11 Astellas Pharma Inc 17-BETA-HSD-type-5 INHIBITOR
WO2007099200A1 (en) 2006-03-03 2007-09-07 Orion Corporation Selective androgen receptor modulators
CN101032486B (zh) 2006-03-08 2011-05-11 张宏 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
PT2656842T (pt) * 2006-03-27 2016-10-04 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
EP2013187B1 (en) 2006-03-29 2014-10-29 The Regents of The University of California Diarylthiohydantoin compounds
GB0610765D0 (en) 2006-05-31 2006-07-12 Proskelia Sas Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
WO2008112941A1 (en) 2007-03-13 2008-09-18 Board Of Regents The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
US8236983B2 (en) 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2871177B1 (en) 2007-09-11 2019-07-17 GTX, Inc. Solid form of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
AR069039A1 (es) 2007-10-26 2009-12-23 Univ California Compuestos de diarilhidantoina, composicion farmaceutica, proceso de obtencion del compuesto, utiles para desordenes hiperproliferativos
US9487479B2 (en) 2008-08-22 2016-11-08 The University Of British Columbia Small molecule inhibitors of N-terminus activation of the androgen receptor
CA2753425A1 (en) 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds
FR2944525B1 (fr) 2009-04-17 2011-06-24 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
EP3357917A1 (en) * 2010-02-16 2018-08-08 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
SI3329775T1 (sl) 2010-02-24 2021-09-30 Medivation Prostate Therapeutics Llc Procesi za sintezo spojin diariltiohidantoina in diarilhidantoina
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US9085539B2 (en) 2010-07-22 2015-07-21 Alexandre Vasilievich Ivachtchenko Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
WO2012050868A1 (en) 2010-09-28 2012-04-19 Georgia Tech Research Corporation Histone deacetylase (hdac) inhibitors targeting prostate tumors and methods of making and using thereof
EP2683694B1 (en) 2011-03-10 2016-04-27 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
US20140248263A1 (en) 2011-04-08 2014-09-04 The University Of British Columbia Bisphenol compounds and methods for their use
BR112013026905B1 (pt) 2011-04-21 2021-09-14 Orion Corporation Compostos de carboxamida moduladora do receptor de andrógeno e seu uso no tratamento e prevenção de câncer de próstata, bem como composições farmacêuticas compreendendo os ditos compostos
UY34078A (es) 2011-05-17 2012-11-30 Takeda Pharmaceutical Composiciones farmacéuticas y métodos para tratar el cáncer
EP2744773B1 (en) 2011-08-19 2016-11-02 British Columbia Cancer Agency Branch Fluorinated bisphenol ether compounds and methods for their use
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
US20130079241A1 (en) 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
JP2014237589A (ja) 2011-09-28 2014-12-18 日本曹達株式会社 環状アミン化合物および有害生物防除剤
WO2013056547A1 (zh) 2011-10-22 2013-04-25 Chen Degui 一组乙内酰脲衍生物的合成及其应用
WO2013067151A1 (en) 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives
WO2013067142A1 (en) 2011-11-02 2013-05-10 Medivation Technologies, Inc. Compounds and treatment methods
MY175800A (en) 2011-11-30 2020-07-09 Astrazeneca Ab Combination treatment of cancer
US9255086B2 (en) 2012-02-16 2016-02-09 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
UA115447C2 (uk) 2012-06-26 2017-11-10 Байєр Фарма Акцієнгезелльшафт N-[4-(хінолін-4-ілокси)циклогексил(метил)](гетеро)арилкарбоксаміди як антагоністи андрогенного рецептора, їх одержання і застосування як лікарських засобів
RS61242B1 (sr) 2012-09-04 2021-01-29 Shanghai hengrui pharmaceutical co ltd Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini
UA124967C2 (uk) 2012-09-26 2021-12-22 Араґон Фармасьютікалз, Інк. Антиандрогени для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
EP2911666B1 (en) 2012-10-26 2022-08-24 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor
EP2912194B1 (en) 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
WO2014075387A1 (zh) 2012-11-14 2014-05-22 上海医药集团股份有限公司 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
AP2015008444A0 (en) 2012-12-03 2015-05-31 Pfizer Novel selective androgen receptor modulators
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014125121A1 (en) 2013-02-18 2014-08-21 Acadia Pharmaceuticals Inc. Compounds and compositions for treating neurodegenerative diseases
EP3327144B1 (en) 2013-02-25 2020-03-25 Novartis AG Novel androgen receptor mutation
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
CN104341396A (zh) * 2013-08-08 2015-02-11 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
EP3046561B1 (en) 2013-09-20 2023-02-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP3089974B1 (en) 2013-12-31 2019-02-20 Ipsen Pharma S.A.S. Novel imidazolidine-2,4-dione derivatives
CN104844521B (zh) 2014-02-13 2017-08-15 成都伊诺达博医药科技有限公司 抗前列腺癌药物恩杂鲁胺的合成方法
PT3149001T (pt) 2014-05-28 2019-07-25 Novartis Ag Novos derivados de pirazolee pirimidina e seu uso como inibidores de malt1
BR112016027691B1 (pt) 2014-05-29 2019-07-02 Taiho Pharmaceutical Co., Ltd. Composto de tetra-hidropiridopirimidina e seus usos
CA2948643C (en) 2014-05-30 2022-09-06 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use

Also Published As

Publication number Publication date
NI201800075A (es) 2018-11-22
MA43864A (fr) 2018-11-21
AU2021201018A1 (en) 2021-03-11
PH12018501413A1 (en) 2019-01-28
US20180298021A1 (en) 2018-10-18
TW201730182A (zh) 2017-09-01
JP2019504836A (ja) 2019-02-21
US10000502B2 (en) 2018-06-19
US20200109150A1 (en) 2020-04-09
CR20190232A (es) 2019-09-11
CR20180352A (es) 2018-11-07
SG11201805685PA (en) 2018-07-30
AU2017207268B2 (en) 2019-02-14
US20170233401A1 (en) 2017-08-17
WO2017123542A1 (en) 2017-07-20
CN108473471A (zh) 2018-08-31
CO2018007738A2 (es) 2018-07-31
EP3402791A1 (en) 2018-11-21
ECSP18060342A (es) 2018-08-31
EA201891615A1 (ru) 2018-12-28
CA3010509A1 (en) 2017-07-20
IL260307A (en) 2018-08-30
NZ744137A (en) 2020-07-31
EA037753B1 (ru) 2021-05-18
BR112018014015A2 (pt) 2018-12-11
US10501469B2 (en) 2019-12-10
KR20180100214A (ko) 2018-09-07
MX2018008502A (es) 2019-06-20
US10981926B2 (en) 2021-04-20
AU2019203280A1 (en) 2019-05-30
TWI726969B (zh) 2021-05-11
AU2017207268A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001230A1 (es) Tratamiento de osteoartritis
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
CL2017001181A1 (es) Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4)
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
ECSP21003718A (es) Derivados de triazolquinoxalina adicionalmente sustituidos
CO2017001523A2 (es) Novedosas pirimidinas 2,5-sustituidas
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
EA202190527A1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
CL2016002066A1 (es) Derivados de indolarilsulfonamida como antagonistas del receptor 5-ht6